{ "run": { "id": "cmnr14yf405yip658fggghx9f", "region": "US", "assetId": "cmnr14yek05yep658ep5mu0vr", "ticker": "REGN", "snapshotId": "cmnr14yeq05ygp658uuz15447", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:41.437Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr14yeq05ygp658uuz15447", "assetId": "cmnr14yek05yep658ep5mu0vr", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 765.26, "price": 775.53, "dayLow": 755.99, "volume": 580427, "dayHigh": 775.625, "currency": "USD", "prevClose": 760.27, "week52Low": 476.4869, "week52High": 821.11 }, "fundamentals": { "pe": 17.9212909217553, "beta": 0.602297823514402, "epsTTM": 43.07, "fcfTTM": null, "growth": { "epsYoy": 0.05305623471882645, "revenueYoy": 0.00992113786790593 }, "sector": "Pharmaceutical Preparations", "margins": { "net": 0.314085714883322, "gross": null, "operating": 0.2494544339010939 }, "website": "https://www.regeneron.com/", "industry": "Pharmaceuticals", "pegRatio": 3.37779169907738, "ebitdaTTM": 6345400000, "forwardPe": 22.2890557320243, "marketCap": 54800000000, "totalCash": 3118100000, "totalDebt": 1985900000, "debtEquity": 0.0635347715224478, "quickRatio": 3.284108598113726, "revenueTTM": 14342900000, "companyName": "REGENERON PHARMACEUTICALS, INC.", "priceToBook": 2.58303293032898, "currentRatio": 4.125515062723194, "dividendYield": 0.0046644932555713, "returnOnAssets": 0.1110711142122405, "returnOnEquity": 0.144124977205033, "analystOpinions": null, "businessSummary": "Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.", "enterpriseValue": 79605402000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 15410, "sharesOutstanding": 93955110, "enterpriseToEbitda": 12.54537176537334, "analystTargetMedian": null, "enterpriseToRevenue": 5.55016084613293, "operatingCashflowTTM": 4978900000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:41.426Z" }, "results": [ { "id": "cmnr14yf605ykp6582m2v0aji", "runId": "cmnr14yf405yip658fggghx9f", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"REGN\",\"currency\":\"USD\",\"current_price\":775.53,\"target_price_6m\":798,\"target_price_12m\":815,\"recommendation\":\"HOLD\",\"confidence\":0.6,\"thesis_bullets\":[\"Dupixent franchise remains key long-term growth engine across expanding indications\",\"Eylea biosimilar competition pressures near-term revenue and margins\",\"Fortress balance sheet with net cash supports pipeline R&D investment\",\"PEG ratio of 3.4x signals limited value relative to current growth trajectory\",\"Pipeline optionality (linvoseltamab, fianlimab) provides medium-term catalysts\"],\"key_drivers\":[{\"driver\":\"Dupixent global sales growth and new indication approvals\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Eylea/Eylea HD biosimilar erosion headwinds\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Linvoseltamab (BCMA bispecific) pivotal data and launch\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Fianlimab (anti-LAG3) oncology pipeline progress\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Sanofi profit-share dynamics on Dupixent\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory and pricing environment for biologics\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Strong cash generation enabling M&A or buybacks\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Revenue growth deceleration to ~1% YoY\",\"impact\":\"HIGH\",\"direction\":\"NEG\"}],\"risks\":[\"Eylea biosimilar uptake faster than modeled, accelerating revenue decline\",\"Key pipeline asset clinical failure (linvoseltamab or fianlimab)\",\"IRA drug price negotiation impacts on Dupixent or future products\",\"Dupixent competitive threat from oral JAK inhibitors or IL-13 alternatives\",\"Sanofi renegotiation of Dupixent collaboration terms unfavorable to REGN\",\"Macro biotech sector de-rating compresses valuation multiples\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.27,\"wacc\":0.085,\"terminal_multiple\":18},\"scenarios\":{\"bear\":{\"target_price\":620,\"prob\":0.2,\"notes\":\"Eylea erosion accelerates, pipeline setbacks compress multiple to ~15x on lower EPS.\"},\"base\":{\"target_price\":815,\"prob\":0.55,\"notes\":\"Dupixent growth offsets Eylea decline; EPS grows modestly to ~$45, P/E holds ~18x.\"},\"bull\":{\"target_price\":950,\"prob\":0.25,\"notes\":\"Pipeline catalysts and Dupixent beat drive EPS to ~$48 with multiple expansion to ~20x.\"}},\"method_notes\":\"Blended P/E and EV/EBITDA valuation anchored on TTM EPS of $43.07 and forward growth assumptions. Base case assumes modest EPS growth (~4-5%) with stable ~18x multiple, yielding ~5% 12M return consistent with HOLD. Forward P/E (22.3x) above trailing (17.9x) flags potential EPS compression risk from Eylea biosimilar headwinds. Strong balance sheet (net cash ~$1.1B, quick ratio 3.3x) provides downside cushion. Sell-side targets not used as numeric inputs. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "ai-equity-research-v1", "risks": [ "Eylea biosimilar uptake faster than modeled, accelerating revenue decline", "Key pipeline asset clinical failure (linvoseltamab or fianlimab)", "IRA drug price negotiation impacts on Dupixent or future products", "Dupixent competitive threat from oral JAK inhibitors or IL-13 alternatives", "Sanofi renegotiation of Dupixent collaboration terms unfavorable to REGN", "Macro biotech sector de-rating compresses valuation multiples" ], "ticker": "REGN", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Dupixent growth offsets Eylea decline; EPS grows modestly to ~$45, P/E holds ~18x.", "target_price": 815 }, "bear": { "prob": 0.2, "notes": "Eylea erosion accelerates, pipeline setbacks compress multiple to ~15x on lower EPS.", "target_price": 620 }, "bull": { "prob": 0.25, "notes": "Pipeline catalysts and Dupixent beat drive EPS to ~$48 with multiple expansion to ~20x.", "target_price": 950 } }, "confidence": 0.6, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 18, "ebit_margin_target": 0.27 }, "key_drivers": [ { "driver": "Dupixent global sales growth and new indication approvals", "impact": "HIGH", "direction": "POS" }, { "driver": "Eylea/Eylea HD biosimilar erosion headwinds", "impact": "HIGH", "direction": "NEG" }, { "driver": "Linvoseltamab (BCMA bispecific) pivotal data and launch", "impact": "MED", "direction": "POS" }, { "driver": "Fianlimab (anti-LAG3) oncology pipeline progress", "impact": "MED", "direction": "POS" }, { "driver": "Sanofi profit-share dynamics on Dupixent", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory and pricing environment for biologics", "impact": "MED", "direction": "NEG" }, { "driver": "Strong cash generation enabling M&A or buybacks", "impact": "MED", "direction": "POS" }, { "driver": "Revenue growth deceleration to ~1% YoY", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Blended P/E and EV/EBITDA valuation anchored on TTM EPS of $43.07 and forward growth assumptions. Base case assumes modest EPS growth (~4-5%) with stable ~18x multiple, yielding ~5% 12M return consistent with HOLD. Forward P/E (22.3x) above trailing (17.9x) flags potential EPS compression risk from Eylea biosimilar headwinds. Strong balance sheet (net cash ~$1.1B, quick ratio 3.3x) provides downside cushion. Sell-side targets not used as numeric inputs. Not investment advice.", "current_price": 775.53, "recommendation": "HOLD", "thesis_bullets": [ "Dupixent franchise remains key long-term growth engine across expanding indications", "Eylea biosimilar competition pressures near-term revenue and margins", "Fortress balance sheet with net cash supports pipeline R&D investment", "PEG ratio of 3.4x signals limited value relative to current growth trajectory", "Pipeline optionality (linvoseltamab, fianlimab) provides medium-term catalysts" ], "target_price_6m": 798, "target_price_12m": 815 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 39365, "createdAt": "2026-04-09T05:21:41.437Z", "usage": { "inputTokens": 3611, "outputTokens": 1854, "costUsd": 0.064405 } }, { "id": "cmnr14yf605ynp658ubqyvj9s", "runId": "cmnr14yf405yip658fggghx9f", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity_Research_Model_v1\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"REGN\",\n \"currency\": \"USD\",\n \"current_price\": 775.53,\n \"target_price_6m\": 796.0,\n \"target_price_12m\": 816.3,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\"Strong balance sheet with low debt and high profitability.\", \"Modest revenue growth supported by existing products.\", \"Valuation in line with historical and peer averages.\", \"Pipeline innovations offer potential for future upside.\", \"Market multiple could re-rate with positive data.\"],\n \"key_drivers\": [\n {\"driver\": \"Pipeline success\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Revenue growth rate\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Operating margin stability\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Regulatory approvals\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Competitive pressure\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n {\"driver\": \"Macroeconomic conditions\", \"impact\": \"LOW\", \"direction\": \"NEG\"}\n ],\n \"risks\": [\"Clinical trial setbacks\", \"Patent cliffs on key drugs\", \"Changes in healthcare policy\", \"Adverse currency movements\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.25,\n \"wacc\": 0.085,\n \"terminal_multiple\": 18\n },\n \"scenarios\": {\n \"bear\": {\"target_price\": 698.0, \"prob\": 0.2, \"notes\": \"Negative pipeline outcomes and multiple contraction.\"},\n \"base\": {\"target_price\": 816.3, \"prob\": 0.6, \"notes\": \"Stable growth and maintained current multiples.\"},\n \"bull\": {\"target_price\": 891.86, \"prob\": 0.2, \"notes\": \"Successful new launches and multiple expansion.\"}\n },\n \"method_notes\": \"Valuation using forward EPS growth and target PE multiple. HOLD as upside limited to ~5% with balanced risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "Equity_Research_Model_v1", "risks": [ "Clinical trial setbacks", "Patent cliffs on key drugs", "Changes in healthcare policy", "Adverse currency movements" ], "ticker": "REGN", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Stable growth and maintained current multiples.", "target_price": 816.3 }, "bear": { "prob": 0.2, "notes": "Negative pipeline outcomes and multiple contraction.", "target_price": 698 }, "bull": { "prob": 0.2, "notes": "Successful new launches and multiple expansion.", "target_price": 891.86 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 18, "ebit_margin_target": 0.25 }, "key_drivers": [ { "driver": "Pipeline success", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue growth rate", "impact": "MED", "direction": "POS" }, { "driver": "Operating margin stability", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approvals", "impact": "HIGH", "direction": "POS" }, { "driver": "Competitive pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Macroeconomic conditions", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation using forward EPS growth and target PE multiple. HOLD as upside limited to ~5% with balanced risks. Not investment advice.", "current_price": 775.53, "recommendation": "HOLD", "thesis_bullets": [ "Strong balance sheet with low debt and high profitability.", "Modest revenue growth supported by existing products.", "Valuation in line with historical and peer averages.", "Pipeline innovations offer potential for future upside.", "Market multiple could re-rate with positive data." ], "target_price_6m": 796, "target_price_12m": 816.3 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 370, "createdAt": "2026-04-09T05:21:41.437Z", "usage": { "inputTokens": 2119, "outputTokens": 4272, "costUsd": 0.002388 } }, { "id": "cmnr14yf605ylp6589c1jbb5w", "runId": "cmnr14yf405yip658fggghx9f", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch-Alpha-v1\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"REGN\",\n \"currency\": \"USD\",\n \"current_price\": 775.53,\n \"target_price_6m\": 780.0,\n \"target_price_12m\": 790.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Dupixent remains a strong growth engine with expanding indications in COPD and EoE.\",\n \"Eylea franchise faces intense competitive pressure from Roche's Vabysmo and looming biosimilars.\",\n \"High dose Eylea (8mg) transition is critical to defending market share in ophthalmology.\",\n \"Oncology portfolio (Libtayo) shows promise but remains a smaller portion of total revenues.\",\n \"Valuation appears full given sluggish near-term revenue growth and expected earnings contraction.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Dupixent sales growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Eylea 8mg market penetration\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Vabysmo competition\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Pipeline R&D success\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operating margin compression\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Capital allocation and buybacks\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Faster-than-expected erosion of standard Eylea sales due to biosimilars.\",\n \"Regulatory delays or clinical trial failures in the oncology or immunology pipeline.\",\n \"Pricing pressures from the Inflation Reduction Act (IRA) impacting Medicare Part B/D.\",\n \"Over-reliance on the Sanofi partnership for Dupixent commercialization.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.03,\n \"ebit_margin_target\": 0.28,\n \"wacc\": 0.075,\n \"terminal_multiple\": 15.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 620.0,\n \"prob\": 0.25,\n \"notes\": \"Eylea franchise collapses under competition and pipeline fails to offset losses.\"\n },\n \"base\": {\n \"target_price\": 790.0,\n \"prob\": 0.55,\n \"notes\": \"Dupixent growth balances Eylea erosion, maintaining stable but low-growth earnings.\"\n },\n \"bull\": {\n \"target_price\": 950.0,\n \"prob\": 0.2,\n \"notes\": \"Eylea HD dominates, Dupixent exceeds COPD expectations, and oncology pipeline delivers blockbusters.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF (7.5% WACC, 3% terminal growth) and an 18x forward P/E multiple. Recommendation is HOLD due to mixed evidence: strong Dupixent growth offset by Eylea competition and sluggish near-term EPS growth. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "EquityResearch-Alpha-v1", "risks": [ "Faster-than-expected erosion of standard Eylea sales due to biosimilars.", "Regulatory delays or clinical trial failures in the oncology or immunology pipeline.", "Pricing pressures from the Inflation Reduction Act (IRA) impacting Medicare Part B/D.", "Over-reliance on the Sanofi partnership for Dupixent commercialization." ], "ticker": "REGN", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Dupixent growth balances Eylea erosion, maintaining stable but low-growth earnings.", "target_price": 790 }, "bear": { "prob": 0.25, "notes": "Eylea franchise collapses under competition and pipeline fails to offset losses.", "target_price": 620 }, "bull": { "prob": 0.2, "notes": "Eylea HD dominates, Dupixent exceeds COPD expectations, and oncology pipeline delivers blockbusters.", "target_price": 950 } }, "confidence": 0.65, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.03, "terminal_multiple": 15, "ebit_margin_target": 0.28 }, "key_drivers": [ { "driver": "Dupixent sales growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Eylea 8mg market penetration", "impact": "HIGH", "direction": "POS" }, { "driver": "Vabysmo competition", "impact": "HIGH", "direction": "NEG" }, { "driver": "Pipeline R&D success", "impact": "MED", "direction": "POS" }, { "driver": "Operating margin compression", "impact": "MED", "direction": "NEG" }, { "driver": "Capital allocation and buybacks", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on a 10-year DCF (7.5% WACC, 3% terminal growth) and an 18x forward P/E multiple. Recommendation is HOLD due to mixed evidence: strong Dupixent growth offset by Eylea competition and sluggish near-term EPS growth. Not investment advice.", "current_price": 775.53, "recommendation": "HOLD", "thesis_bullets": [ "Dupixent remains a strong growth engine with expanding indications in COPD and EoE.", "Eylea franchise faces intense competitive pressure from Roche's Vabysmo and looming biosimilars.", "High dose Eylea (8mg) transition is critical to defending market share in ophthalmology.", "Oncology portfolio (Libtayo) shows promise but remains a smaller portion of total revenues.", "Valuation appears full given sluggish near-term revenue growth and expected earnings contraction." ], "target_price_6m": 780, "target_price_12m": 790 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 38141, "createdAt": "2026-04-09T05:21:41.437Z", "usage": { "inputTokens": 2466, "outputTokens": 885, "costUsd": 0.015552 } }, { "id": "cmnr14yf605yjp658xxafrp3m", "runId": "cmnr14yf405yip658fggghx9f", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"REGN\",\"currency\":\"USD\",\"current_price\":775.53,\"target_price_6m\":798,\"target_price_12m\":815,\"recommendation\":\"HOLD\",\"confidence\":0.64,\"thesis_bullets\":[\"High-margin franchise with strong balance sheet limits downside.\",\"Current valuation already reflects much of quality and durability.\",\"Near-term growth looks modest versus premium biotech peers.\",\"Pipeline and label-expansion optionality support medium-term upside.\",\"Mixed growth visibility argues fair-value stance today.\"],\"key_drivers\":[{\"driver\":\"Dupixent royalty growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Eylea franchise stability\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Pipeline readouts\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Oncology commercialization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Operating margin resilience\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Patent and biosimilar pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Capital allocation discipline\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Low leverage and liquidity\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Key trial failures or delays\",\"Faster Eylea erosion\",\"Drug pricing or rebate pressure\",\"Partner concentration on Dupixent\",\"Higher R&D spend without revenue payback\"],\"assumptions\":{\"revenue_cagr_3y\":0.07,\"ebit_margin_target\":0.3,\"wacc\":0.085,\"terminal_multiple\":15},\"scenarios\":{\"bear\":{\"target_price\":660,\"prob\":0.25,\"notes\":\"Legacy eye-care weakness and weaker pipeline conversion compress valuation.\"},\"base\":{\"target_price\":815,\"prob\":0.5,\"notes\":\"Solid cash generation offsets only moderate top-line growth.\"},\"bull\":{\"target_price\":960,\"prob\":0.25,\"notes\":\"Pipeline wins and stronger immunology growth expand earnings power.\"}},\"method_notes\":\"Targets use a blended forward earnings/EV-EBIT framework anchored to snapshot fundamentals and stated assumptions; no sell-side targets used. Snapshot quote fields kept authoritative. Recommendation is HOLD because 12M upside is about 5.1%, inside the rubric band; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Model Recommendation", "risks": [ "Key trial failures or delays", "Faster Eylea erosion", "Drug pricing or rebate pressure", "Partner concentration on Dupixent", "Higher R&D spend without revenue payback" ], "ticker": "REGN", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Solid cash generation offsets only moderate top-line growth.", "target_price": 815 }, "bear": { "prob": 0.25, "notes": "Legacy eye-care weakness and weaker pipeline conversion compress valuation.", "target_price": 660 }, "bull": { "prob": 0.25, "notes": "Pipeline wins and stronger immunology growth expand earnings power.", "target_price": 960 } }, "confidence": 0.64, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.07, "terminal_multiple": 15, "ebit_margin_target": 0.3 }, "key_drivers": [ { "driver": "Dupixent royalty growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Eylea franchise stability", "impact": "HIGH", "direction": "NEG" }, { "driver": "Pipeline readouts", "impact": "HIGH", "direction": "POS" }, { "driver": "Oncology commercialization", "impact": "MED", "direction": "POS" }, { "driver": "Operating margin resilience", "impact": "MED", "direction": "POS" }, { "driver": "Patent and biosimilar pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Capital allocation discipline", "impact": "LOW", "direction": "POS" }, { "driver": "Low leverage and liquidity", "impact": "MED", "direction": "POS" } ], "method_notes": "Targets use a blended forward earnings/EV-EBIT framework anchored to snapshot fundamentals and stated assumptions; no sell-side targets used. Snapshot quote fields kept authoritative. Recommendation is HOLD because 12M upside is about 5.1%, inside the rubric band; not investment advice.", "current_price": 775.53, "recommendation": "HOLD", "thesis_bullets": [ "High-margin franchise with strong balance sheet limits downside.", "Current valuation already reflects much of quality and durability.", "Near-term growth looks modest versus premium biotech peers.", "Pipeline and label-expansion optionality support medium-term upside.", "Mixed growth visibility argues fair-value stance today." ], "target_price_6m": 798, "target_price_12m": 815 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0e380b02488260840069d75cd36c9081958b55f696246d4db4", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 19534, "createdAt": "2026-04-09T05:21:41.437Z", "usage": { "inputTokens": 2393, "outputTokens": 1005, "costUsd": 0.018258 } }, { "id": "cmnr14yf605ymp6586sisytrr", "runId": "cmnr14yf405yip658fggghx9f", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"REGN\",\n \"currency\": \"USD\",\n \"current_price\": 775.53,\n \"target_price_6m\": 785,\n \"target_price_12m\": 810,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Dupixent drives immunology franchise leadership\",\n \"Eylea faces biosimilar competition pressure\",\n \"Strong cash flow funds R&D investment\",\n \"Oncology pipeline offers future growth potential\",\n \"Current valuation limits near-term upside\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Dupixent sales momentum\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Eylea biosimilar competition\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Pipeline approvals and launches\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"R&D clinical success rate\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"EBIT margin sustainability\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory approval risks\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Business development activity\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Patent expirations on core products\",\n \"Clinical trial failures or delays\",\n \"Increased competition in key areas\",\n \"Drug pricing and reimbursement pressure\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.28,\n \"wacc\": 0.085,\n \"terminal_multiple\": 15\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 620,\n \"prob\": 0.3,\n \"notes\": \"Pipeline delays and competition erode market share.\"\n },\n \"base\": {\n \"target_price\": 810,\n \"prob\": 0.5,\n \"notes\": \"Moderate growth from core products and select launches.\"\n },\n \"bull\": {\n \"target_price\": 1050,\n \"prob\": 0.2,\n \"notes\": \"Blockbuster pipeline success and margin expansion.\"\n }\n },\n \"method_notes\": \"DCF using 8% rev CAGR, 28% EBIT margin, 8.5% WACC, 15x terminal. Mixed low growth vs strong margins supports HOLD. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Equity Research Model", "risks": [ "Patent expirations on core products", "Clinical trial failures or delays", "Increased competition in key areas", "Drug pricing and reimbursement pressure" ], "ticker": "REGN", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate growth from core products and select launches.", "target_price": 810 }, "bear": { "prob": 0.3, "notes": "Pipeline delays and competition erode market share.", "target_price": 620 }, "bull": { "prob": 0.2, "notes": "Blockbuster pipeline success and margin expansion.", "target_price": 1050 } }, "confidence": 0.6, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.08, "terminal_multiple": 15, "ebit_margin_target": 0.28 }, "key_drivers": [ { "driver": "Dupixent sales momentum", "impact": "HIGH", "direction": "POS" }, { "driver": "Eylea biosimilar competition", "impact": "HIGH", "direction": "NEG" }, { "driver": "Pipeline approvals and launches", "impact": "HIGH", "direction": "POS" }, { "driver": "R&D clinical success rate", "impact": "MED", "direction": "POS" }, { "driver": "EBIT margin sustainability", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approval risks", "impact": "MED", "direction": "NEG" }, { "driver": "Business development activity", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF using 8% rev CAGR, 28% EBIT margin, 8.5% WACC, 15x terminal. Mixed low growth vs strong margins supports HOLD. Not investment advice.", "current_price": 775.53, "recommendation": "HOLD", "thesis_bullets": [ "Dupixent drives immunology franchise leadership", "Eylea faces biosimilar competition pressure", "Strong cash flow funds R&D investment", "Oncology pipeline offers future growth potential", "Current valuation limits near-term upside" ], "target_price_6m": 785, "target_price_12m": 810 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "c3942304-90ec-9554-808e-94c591b2b90b", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 24566, "createdAt": "2026-04-09T05:21:41.437Z", "usage": { "inputTokens": 2729, "outputTokens": 4232, "costUsd": 0.071667 } } ] } }